Corcept Therapeutics INC Form 4 insider transactions

Sean Maduck, President of Corcept Endocrinology, reports the acquisition and disposal of Corcept Therapeutics stock and derivative securities on February 3, 2025.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on February 3, 2025, according to a Form 4 filing.

Director James N. Wilson reports a gift of 7,800 common stock shares and updates beneficial ownership in Corcept Therapeutics.

Director James N. Wilson exercised stock options and transferred shares, resulting in changes to his beneficial ownership of Corcept Therapeutics stock.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on January 10, 2025, according to a recent SEC filing.

A Corcept Therapeutics executive, Sean Maduck, sold 20,000 shares of common stock after exercising options, according to a recent SEC filing.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and sold shares on January 2, 2025, according to a recent SEC filing.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, executed stock options and sold shares, according to a recent SEC filing.

Director G. Leonard Baker Jr. of Corcept Therapeutics reported a transfer of shares through a gift of limited partnership interests and holdings through a limited partnership and trust.

Director James N. Wilson reported a transfer of 7,800 common shares to a trust, maintaining indirect beneficial ownership.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on December 10, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer at Corcept Therapeutics, sold 309 shares of common stock to cover tax obligations related to vesting restricted stock units.

Corcept Therapeutics officer Sean Maduck reports acquiring and disposing of company stock, including shares withheld for tax obligations and new shares purchased under a company plan.

Gary Robb, Chief Business Officer at Corcept Therapeutics, reported the acquisition and disposal of company stock, including shares withheld for tax obligations and new shares purchased under a company plan.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, reported the acquisition and disposal of company shares on December 2, 2024.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported the acquisition and disposal of company shares on December 2, 2024, including shares withheld for tax obligations and shares purchased under a company plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, sold 2,609 shares and gifted 300 shares of company stock, according to a recent SEC Form 4 filing.

A Corcept Therapeutics officer, Joseph Douglas Lyon, sold 1,411 shares of common stock at $56.72 per share on November 22, 2024.

A Corcept Therapeutics director, Daniel N. Swisher Jr., exercised stock options and sold shares on November 11, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares on October 1, 2024, according to a Form 4 filing with the SEC.

Chief Business Officer Gary Charles Robb reported gifting shares and holding shares in custodial accounts for a child.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports stock transactions including tax withholding and purchase plan acquisitions.

Atabak Mokari, CFO of Corcept Therapeutics, reports the acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under a company purchase plan.

Sean Maduck, President of Corcept Endocrinology, reports acquisition and disposal of Corcept Therapeutics (CORT) stock, including shares withheld for tax obligations and shares purchased under an incentive plan.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under an incentive award plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, sold 3,101 shares of common stock at $35.71 per share on August 26, 2024.

Director Daniel N. Swisher, Jr. of Corcept Therapeutics reports the exercise of stock options and subsequent sale of shares on August 1, 2024.